<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: This study aimed to elucidate the influence of <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU)-based therapy on the vascular endothelium and its association with 5-FU-induced heart <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The study prospectively accrued patients (n = 106) having completely resected <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and receiving adjuvant treatment with 5-FU, folinic acid, and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The levels of plasma <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWf), urine albumin-to-<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (UACR), coagulation factor II + VII + X, and fibrin D-dimer were serially assessed before, during, and after chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The vWf level increased from median (range) 1.43 kU/l (0.48 to &gt;3) to 2.64 kU/l (0.23 to &gt;3) (P = 0.001), the UACR increased from 1.1 ± 0.2 mg/mmol (mean ± SE) to 2.1 ± 0.3 mg/mmol (P = 0.001), the coagulation factor II + VII + X activity decreased from 1.00 ± 0.02 to 0.94 ± 0.02 U/l (P = 0.001), and the fibrin D-dimer level increased from 1.1 ± 0.2 to 2.1 ± 0.3 kU/l (P = 0.001) at baseline and during chemotherapy, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The changes in the levels of vWf (P = 0.3), UACR (P = 0.8), coagulation factor II + VII + X (P = 0.8), and fibrin D-dimer (P = 0.6) in nine (8.5%) patients having clinical signs of cardiotoxicity were not significantly different from that of the patients not having cardiotoxicity </plain></SENT>
<SENT sid="5" pm="."><plain>The 5-FU-induced rise in plasma biomarkers was not significantly related to the <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> or its risk factors (P = 0.9) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: 5-FU therapy induces global reversible endothelial injury leading to a procoagulant state </plain></SENT>
<SENT sid="7" pm="."><plain>The ensuing <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> may be of significance to the pathogenesis of 5-FU-induced clinically overt cardiotoxicity </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> is not significant for the vulnerability of the endothelium to 5-FU-based chemotherapy </plain></SENT>
</text></document>